Evaluation of CA-125 as an Indicator of Imaging During Follow-up of Carcinoma Ovary: Original Research.

Abstract

Women with response to primary treatment for advanced ovarian cancer are said to have progression if CA125 increases more than double the upper normal limit (70IU/L) on follow-up. It was, however, noted that large section of women with CA125 > 35IU/L had disease on imaging. To compare values of CA125 rise at which radiological recurrence can be detected. This is a retrospective observational study where women with advanced epithelial ovarian cancer who underwent interval debulking surgery and completed treatment at Tata Medical Center, Kolkata, India, from 2012 to 2016, and were followed up with Ca125. If CA125 doubled or exceeded 35IU/L or increased to ≥ 70IU/L, women were subjected to imaging. Among 142 women who underwent treatment, 64 women with response to primary treatment had recurrence. Recurrence was noted in two (3%) patients with doubling of Ca125 but ≤ 35IU/, 18 (24%) patients with CA125 > 35IU/L and 41 (64%) patients when CA125 was ≥ 70IU/L. Three patients (5%) with normal CA125 had recurrence. Among the recurrence group, 45 women had R0 during surgery of which 27 (60%) had CA125 ≥ 70IU/L and 14 (31%) had CA125 > 35IU/L during recurrence. Sensitivity and specificity of value > 35IU/L were 30.51% and 33.33%, respectively, with accuracy of 32.03%, while sensitivity and specificity at > 70IU/L were 69.49% and 66.67%, respectively, with accuracy of 67.97%. CA125 value of ≥ 70IU/L is a better predictor of recurrence; however, imaging done when value rises > 35IU/L would be able to detect significant recurrences early thus allowing early treatment.